Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China

Suying Liu1†, Ling Guo2†, Xiaoyuan Fan3, Zhaocui Zhang4, Jiaxin Zhou1, Xinping Tian1, Mengtao Li1, Xiaofeng Zeng1, Li Wang1* and Fengchun Zhang1*

Abstract

Background: Central nervous system (CNS) involvement is extremely rare in eosinophilic granulomatosis with polyangiitis (EGPA), but is associated with a poor prognosis in the five-factor score. This study aims to elucidate the clinical features and independently associated factors of EGPA with CNS involvement.

Results: CNS involvement was observed in 17.3% (19/110) of EGPA patients from Peking Union Medical College Hospital between 2007 and 2019. We retrospectively reviewed their clinical data and analyzed the independently associated factors. Their mean age was 51.7 ± 11.56 years with no male/female predominance. Ischemic lesions were the most common manifestations, accounting for 63.2% of the 19 cases, followed by posterior reversible encephalopathy syndrome (36.8%), spinal cord involvement (15.8%), medulla oblongata involvement (15.8%), and intracranial hemorrhages (15.8%). Compared to the control group, patients with CNS involvement were of older age (51.7 ± 11.56 vs. 43.7 ± 13.78 years, \( p = 0.019 \)) and had a higher ratio in the digestive tract involvement (52.6% vs. 28.6%, \( p = 0.042 \)). Further multivariate analysis revealed that age, disease duration, and fever were the potential independent risk factors for CNS involvement of EGPA. Glucocorticoids combined with cyclophosphamide were the strategic therapy (94.7%). Intrathecal injections of dexamethasone and methotrexate were administered to 21.1% of the patients. Although seven patients relapsed during glucocorticoid reduction, seventeen patients finally achieved clinical remission. One patient died of acute intracerebral hemorrhage within one month, and another died of gastrointestinal perforation. Outcomes and cumulative survival show no significant differences between the two groups.

Conclusions: CNS involvement is uncommon in EGPA with various manifestations, and ischemic lesions are the most frequent. Age, disease duration, and fever are independent factors associated with CNS involvement in EGPA. The therapy of glucocorticoids combined with cyclophosphamide and intrathecal injections yields favorable responses. Acute intracranial hemorrhage and gastrointestinal perforation may be the principal causes of death.
**Background**

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic necrotizing antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Although EGPA was classified as a type of AAV, in the past few decades, researchers have increasingly considered it as a distinct form of AAV with different manifestations and outcomes as compared to granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) [1]. ANCA can be detected in approximately one-third of EGPA patients' serum, and the clinical spectrum and pathogenesis of ANCA-negative and positive EGPA are different [2–4].

EGPA primarily affects the respiratory tract, lungs, peripheral nervous system, heart, gastrointestinal tract, and skin, but central nervous system (CNS) involvement is rarely seen [5–7]. CNS involvement was included in the 1996 five-factor score (FFS) that was associated with a higher risk of death, but it was removed from the 2011 revised FFS system due to its rarity [8, 9]. There are few systematic studies on CNS involvement of EGPA, and most of them are case reports. The largest study at present is a retrospective cohort in France, which included 26 patients with CNS involvement of EGPA [10]. For the Chinese EGPA population with CNS involvement, a comprehensive study has not yet been reported. Therefore, we collected the clinical data of EGPA patients in our hospital, aiming to investigate the clinical features, independently associated factors, treatment, and outcomes.

**Results**

**Features of CNS involvement in EGPA**

A total of 19 EGPA patients developed CNS involvement in this cohort (17.3%). The mean age of EGPA onset was 51.7 years (range 25–72 years) with no female/male predominance. Table 1 shows a summary of CNS involvement in EGPA, and the specific lesion characteristics for each patient are shown in Table 2.

Cerebrovascular events were the most common manifestations (73.7%), including twelve patients with ischemic lesions (85.7%) and three cases with intracranial hemorrhages (21.4%). Semioval centers and basal ganglia were the most frequently affected location (7/14). Among the seven patients with posterior reversible encephalopathy syndrome (PRES), one patient experienced hoarseness, choking on swallowing, limb weakness, loss of consciousness, and sudden epilepsy. In three patients with spinal cord involvement, the thoracic cord was affected in two cases and the cervical cord in one case. Hypertrophic cranial pachymeningitis (HCP) mainly presented with a severe headache. Three patients had medulla oblongata involvement, one of whom had an absent pharyngeal reflex, and another patient complained of headache, convulsion, numbness and weakness, and dizziness. Figure 1 shows the representative magnetic resonance imaging (MRI).

Moreover, 13 cases (68.4%) were accompanied by non-CNS damage that was associated with CNS involvement in EGPA. Ethmoid sinusitis and maxillary sinusitis were found in 11 cases (84.6%), and autonomic nerves were affected in two cases (urinary and fecal incontinence).

**Baseline clinical characteristics of EGPA patients with or without CNS involvement**

We compared the baseline clinical features between patients with CNS involvement and those without CNS involvement (Table 3). The mean age of EGPA onset in the case group was significantly older than that in the control group (51.7 ± 11.56 vs. 43.7 ± 13.78 years, \( p = 0.019 \)). The disease duration in the case group was longer, which was close to the statistical difference [11 (4, 39) vs. 5 (2, 14) months, \( p = 0.082 \)]. Regarding the clinical manifestations, the case group had a higher proportion of digestive tract involvement than

---

**Keywords:** Central nervous system involvement, Eosinophilic granulomatosis with polyangiitis, Churg-Strauss, Clinical features, Associated factors

---

**Table 1 Clinical features of CNS involvement in EGPA (n = 19)**

| Number | Ratio (%) |
|--------|-----------|
| Cerebrovascular events | 14 | 73.7 |
| Ischemic infarctions | 12 | 85.7 |
| Intracranial hemorrhages | 3 | 21.4 |
| Posterior reversible encephalopathy syndrome | 7 | 36.8 |
| Headache | 5 | 71.4 |
| Encephalopathy | 2 | 28.6 |
| Seizures | 1 | 14.3 |
| Spinal cord involvement | 3 | 15.8 |
| Medulla oblongata involvement | 3 | 15.8 |
| Hypertrophic cranial pachymeningitis | 2 | 10.5 |
| Cerebellar ataxia | 2 | 10.5 |
| Non-CNS entities associated with CNS involvement | 13 | 68.4 |
| Paranasal sinusitis | 11 | 84.6 |
| Autonomic nervous dysfunction | 2 | 15.4 |
| Orbital disease | 1 | 7.7 |

CNS, Central Nervous System; EGPA, Eosinophilic Granulomatosis with Polyangiitis.
the control group (52.6% vs. 28.6%, \( p = 0.042 \)). And patients with CNS involvement showed an upward trend of fever incidence (57.9% vs. 37.4%, \( p = 0.098 \)). Other organs, including the heart, lungs, kidneys, muscles, joints, skin, nose, and ears were found no statistical differences between the groups.

| ID  | Sex/age | Lesions features | Lesions location | Induction therapy | Intrathecal injections\(^a\) | FU, months | Outcomes |
|-----|---------|------------------|------------------|-------------------|-----------------------------|------------|----------|
| 1   | F/39    | Ischemic infarctions | Multiple          | MP 80 mg qd      | N                           | 1          | death    |
| 2   | F/46    | Ischemic infarctions | Right semiouate centers | Pred 80 mg qd + CYC | N                           | 84         | remission |
| 3   | M/49    | Ischemic infarctions; PRES | Multiple, subacute cerebral infarcts in left basal ganglia | MP pulse + IVIG + CYC | DXM *3                      | 72         | remission |
| 4   | M/49    | Ischemic infarctions | Basal ganglia     | MP pulse          | N                           | 48         | remission |
| 5   | F/71    | Spinal cord involvement | Thoracic spinal cord | MP 40 mg qd      | N                           | 24         | remission |
| 6   | M/64    | Ischemic infarctions; PRES | Right semiouate centers | MP 80 mg qd + IVIG + CYC | N                           | 46         | remission |
| 7   | M/52    | Ischemic infarctions; PRES; ataxia; | Bilateral basal ganglia; cerebellar ataxia | MP 24 mg qd + CYC + AZA | DXM *1 + MTX *4              | 36         | remission |
| 8   | F/72    | Ischemic infarctions | Multiple lesions in cerebrum | MP 160 mg qd      | N                           | 20         | remission |
| 9   | F/49    | HCP               | Cerebral falx     | MP pulse          | N                           | 15         | remission |
| 10  | F/45    | Ischemic infarctions; PRES | Under bilateral frontal and parieto-occipital cortex | Pred 40 mg qd + CYC | N                           | 42         | remission |
| 11  | F/47    | HCP               | Bilateral brain   | MP pulse          | DXM *5                      | 132        | remission |
| 12  | M/57    | Medulla oblongata and spinal cord lesions | Medulla oblongata and cervical spinal cord | MP pulse | N                           | 17         | remission |
| 13  | F/63    | Ischemic infarctions | Right basal ganglia and white matter | MP pulse | N                           | 12         | remission |
| 14  | F/55    | Intracranial hemorraghes; PRES | Right frontal–temporal lobe | MP pulse + Plasma change + CYC | N                           | 1          | death    |
| 15  | M/46    | Ischemic infarctions | Multiple lesions in cerebrum | MP 40 mg qd + CYC | N                           | 4          | remission |
| 16  | M/25    | Medulla oblongata and spinal cord involvement | Medulla oblongata and thoracic spinal cord | Pred 17.5 mg qd + CYC | N                           | 76         | remission |
| 17  | M/34    | Intracranial hemorraghes | Subarachnoid space | Pred 50 mg qd + CYC | N                           | 9          | remission |
| 18  | M/41    | Ischemic infarctions; PRES; medulla oblongata lesions; ataxia | Subcortex of bilateral frontal parietal lobe; right side of medulla oblongata; cerebellum | MP pulse + IVIG | N                           | 20         | remission |
| 19  | M/64    | Ischemic infarctions; intracranial hemorraghes; PRES | Infarcts in cortex and white matter; cerebral hemorraghes in left basal ganglia, cortex, subcortex and the sulci | MP pulse | DXM *1                      | 6          | remission |

Sex, F-female, M-male; FU, follow-up duration; MP, methylprednisolone; Pred, prednisone; IVIG, intravenous immunoglobulin; CYC, cyclophosphamide; PRES, posterior reversible encephalopathy syndrome; HCP, hypertrophic cranial pachymeningitis

\(^a\) “N” indicates no intrathecal injections were used during the follow-up, and the number after the asterisk refers to the number of intrathecal injections in this column; DXM, Dexamethasone; MTX, methotrexate; AZA, azathioprine

\(^b\) Relapse during glucocorticoid reduction

Independently associated factors for CNS involvement in EGPA patients

Next, we selected factors with two-sided \( p < 0.10 \) to explore independent factors associated with CNS involvement in EGPA by multivariate logistic regression analysis (Table 4). We found that age (odds ratio, OR = 1.045, 95% confidence interval, 95% CI 1.004–1.089), disease duration (OR = 1.018, 95% CI 1.001–1.036), and fever (OR = 3.134, 95% CI 1.007–9.755) were the potential independent risk factors for CNS involvement in EGPA.
Features of the cerebrospinal fluid (CSF)

Seven patients underwent lumbar puncture, and four of them were found to have elevated intracranial pressure (245–300 mmH2O); one patient had bloody CSF due to subarachnoid hemorrhage. CSF protein was mildly increased in four patients (median 0.68 g/L), one of whom was accompanied by slightly raised CSF glucose (5.5 mmol/L).

Treatment and outcomes

The treatment strategy for all EGPA patients with CNS involvement was summarized in Table 5. During the induction phase, glucocorticoids combined with cyclophosphamide (CYC) were used in 94.7% of all patients. Among them, nine patients (47.4%) were used methylprednisolone pulse (0.5–1.0 g/d, 3–5 days), nine patients (47.4%) were administered high-dose glucocorticoids (1–2 mg·kg⁻¹·d⁻¹), and only one patient (5.3%) was administered low-dose glucocorticoids (<0.5 mg·kg⁻¹·d⁻¹) because of mild clinical symptoms. Compared with the control group, the case group had a higher ratio of methylprednisolone pulse (47.4% vs. 24.2%, \( p = 0.041 \)). Additionally, three cases were administered intravenous immunoglobulin (IVIG), and one case was prescribed plasma exchange therapy. Notably, for those with severe CNS lesions (21.1%), we administered intrathecal injections of dexamethasone (10 mg each time) and methotrexate (MTX, 10 mg each time).

In the maintenance treatment stage, low-dose glucocorticoids and the immunosuppressants, including MTX, Tripterygium wilfordii (used in traditional Chinese medicine), and azathioprine, were maintained according to the specific conditions for each patient.

With a mean follow-up of 20 months (range 1–132 months), we witnessed that seventeen patients achieved clinical remission (89.5%), although seven of them relapsed during glucocorticoid reduction. Two patients died: one was due to an acute intracerebral hemorrhage within one month, and the other was due to gastrointestinal perforation. The cumulative survival (Fig. 2) and outcomes (Table 5) do not present significant differences between the groups.

Discussion

In the single-center Chinese EGPA cohort, CNS involvement occurred in 17.3% of patients, which primarily manifested as ischemic lesions, followed by PRES, spinal cord, or medulla oblongata involvement. Age, disease duration, and fever were the independently associated factors for CNS lesions of EGPA. The treatment strategy was glucocorticoids-based immunosuppressive therapy, combined with CYC and intrathecal injections of dexamethasone and MTX.

CNS involvement in the current study was found in less than one-fifth of EGPA patients, suggesting that it was relatively rare compared to peripheral neuropathy in EGPA, which occurred in 46.4% of patients [11]. In studies from other countries, CNS lesions occurred in 5–14% of EGPA patients [7, 12–16], which was lower than that in our cohort. The reason may be that most of the patients admitted to our hospital were referred from the local hospitals with severe conditions. Similarly, CNS lesions were present in 7–16% of GPA [17–19] and 5.8–11.8% of MPA [17, 20, 21], indicating that all three types of AAV rarely affect the CNS.

The clinical manifestations of CNS involvement in EGPA vary widely, and all locations in the CNS could be affected, primarily including ischemic lesions, PRES, spinal cord or medulla oblongata involvement. This indicates the clinical identification complexity of CNS involvement in EGPA. Compared with EGPA, GPA is more prone to HCP [22, 23], and MPA is predominated by cerebrovascular neuropathy [17]. In EGPA, ischemic lesions were more commonly seen and mainly presented with multiple punctate ischemic foci or lacunar infarcts [10, 13]. In our cohort, subarachnoid hemorrhage occurred only in one patient, but previous studies reported a high proportion of subarachnoid hemorrhage [10], which may reflect the differences in ethnic populations and regions, or because our sample size was not large enough.

PRES is associated with autoimmune diseases, which are uncommon but unique in the late stages of AAV [24, 25]. PRES’ symptoms may relapse when the underlying EGPA is not well-controlled. Spinal cord damage usually affects the cervical and thoracic spinal cords, causing motor and sensory deficiencies. Medulla oblongata involvement should be noted considering the location’s...
Table 3 Baseline features of EGPA patients with and without CNS involvement

| Characteristics                        | With CNS involvement (n = 19) | Without CNS involvement (n = 91) | P value |
|----------------------------------------|------------------------------|---------------------------------|---------|
| Demographics                           |                              |                                 |         |
| Age (year)                             | 51.7 ± 11.56                | 43.7 ± 13.78                    | 0.019*  |
| Gender (male/female, number)           | 10/9                        | 51/40                           | 0.490   |
| Time from allergy to EGPA diagnosis (month) | 48 (5, 115)               | 24 (5, 60)                      | 0.314   |
| Disease duration (month)               | 11 (4, 39)                  | 5 (2, 14)                       | 0.082   |
| Time from initial symptoms to vasculitis (month) | 21 (2, 54)               | 7 (0, 36)                       | 0.337   |
| Clinical manifestation, n (%)          |                              |                                 |         |
| Weight loss                            | 6 (31.6)                    | 35 (38.5)                       | 0.573   |
| Fever                                  | 11 (57.9)                   | 34 (37.4)                       | 0.098   |
| Arthritis                              | 4 (21.1)                    | 13 (14.3)                       | 0.489   |
| Myalgia                                | 6 (31.6)                    | 16 (17.6)                       | 0.207   |
| Allergic rhinitis                      | 6 (31.6)                    | 34 (37.4)                       | 0.634   |
| Severe asthma                          | 13 (68.4)                   | 72 (79.1)                       | 0.368   |
| Cutaneous vasculitis                   | 11 (57.9)                   | 48 (52.7)                       | 0.682   |
| Renal involvement                      | 4 (21.1)                    | 24 (26.4)                       | 0.776   |
| Digestive tract involvement            | 10 (52.6)                   | 26 (28.6)                       | 0.042*  |
| Peripheral neuropathy                  | 11 (57.9)                   | 40 (44.0)                       | 0.268   |
| Cardiac involvement                    | 5 (26.3)                    | 35 (38.5)                       | 0.317   |
| Ear involvement                        | 4 (21.1)                    | 10 (11.0)                       | 0.258   |
| Sinusitis                              | 11 (57.9)                   | 53 (58.2)                       | 0.978   |
| Laboratory examination                 |                              |                                 |         |
| Eos count (10^9/L)                     | 4.1 (1, 5.5, 6)             | 2.6 (1.4, 7.6)                  | 0.770   |
| Eos%                                   | 37.2 (11.8, 50.0)           | 28.6 (17.1, 45.7)               | 0.483   |
| ESR (mm/1 h)                           | 27 (9, 40)                  | 32 (14, 54)                     | 0.461   |
| CRP (mg/L)                             | 10.84 (5.34, 39.77)         | 21.70 (4.54, 63.85)             | 0.623   |
| RF (IU/mL)                             | 21.7 (7.09, 1)             | 25.0 (10.0, 90.4)               | 0.651   |
| MPO-ANCA, n (%)                        | 3 (15.8)                    | 12 (13.2)                       | 0.721   |
| PR3-ANCA, n (%)                        | 1 (5.3)                     | 1 (1.1)                         | 0.317   |
| Biopsy-proven vasculitis               | 4 (21.1)                    | 10 (11.0)                       | 0.258   |
| Granuloma, n (%)                       | 1 (5.3)                     | 5 (5.5)                         | 1.000   |
| Clinical score                         |                              |                                 |         |
| BVAS                                    | 16 (14, 22)                 | 14 (10, 19)                     | 0.103   |
| FFS ≥ 1, n (%)                         | 16 (84.2)                   | 65 (71.4)                       | 0.250   |

All the continuous normally distributed data are presented as mean ± standard deviation, and non-normally distributed data as median (first quartile, third quartile).

EGPA, Eosinophilic Granulomatosis with Polyangiitis; CNS, Central Nervous System; Eos, eosinophil; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; MPO, myeloperoxidase; ANCA, anti-neutrophil cytoplasmic antibody; PR3, protease 3; BVAS, Birmingham Vasculitis Activity Score; FFS, five-factor score; *P < 0.05.

Table 4 Multivariate analysis for 19 EGPA patients with CNS involvement and 91 controls

| Variable                              | Odd Ratio | 95% CI      | P value |
|---------------------------------------|-----------|-------------|---------|
| Age (years)                           | 1.045     | 1.004–1.089 | 0.033*  |
| Disease duration (months)             | 1.018     | 1.001–1.036 | 0.039*  |
| Digestive system involvement          | 3.134     | 1.007–9.755 | 0.049*  |

EGPA, Eosinophilic Granulomatosis with Polyangiitis; CNS, Central Nervous System; CI, confidence interval; *P < 0.05.

Table 5 Treatment and outcomes of EGPA patients with and without CNS involvement

| Variable                              | With CNS involvement (n = 19) | Without CNS involvement (n = 91) | P value |
|---------------------------------------|------------------------------|---------------------------------|---------|
| Treatment, n (%)                      |                              |                                 |         |
| GCs                                   | 19 (100)                     | 88 (96.7)                       | 1.000   |
| MP pulse                              | 9 (47.4)                     | 22 (24.2)                       | 0.041*  |
| CYC                                   | 18 (94.7)                    | 80 (87.9)                       | 0.688   |
| Rituximab                             | 0 (0)                        | 1 (1.1)                         | 1.000   |
| Plasma exchange                       | 1 (5.3)                      | 0 (0)                           | 0.173   |
| IVIG                                  | 3 (15.8)                     | 11 (12.1)                       | 0.706   |
| Outcomes, n (%)                       |                              |                                 |         |
| Complete remission                    | 17 (89.5)                    | 73 (80.2)                       | 0.517   |
| Partial relief                        | 0 (0)                        | 12 (13.2)                       | 0.122   |
| Death                                 | 2 (10.5)                     | 6 (6.6)                         | 0.625   |

The categorical variables are expressed as frequencies and ratios, and are further compared by Chi-square analysis or Fisher’s exact test.

EGPA, Eosinophilic Granulomatosis with Polyangiitis; CNS, Central Nervous System; GCs, glucocorticoids (including pulse, high, medium, and low doses); MP, methylprednisolone; CYC, cyclophosphamide (including all kinds of doses); IVIG, Intravenous immunoglobulin; *P < 0.05.

Log-rank test P = 0.5519

Fig. 2 Comparison of cumulative survival rates between EGPA patients with and without central nervous system involvement.
vitality. Contrast-enhanced MRI helps capture abnormal signals in the spinal cord or medulla oblongata earlier.

Patients with CNS lesions are more likely to involve the digestive tract in our study. Age, disease duration, and fever were independently associated factors for CNS involvement in EGPA. Disease duration and fever reflect the inflammatory severity, which plays a pivotal role in CNS lesions, including innate and adaptive immunity and microbiota-gut-brain axis. The gastrointestinal tract is part of the largest immune cell compartments in the body. Therefore, the microbiota-gut-brain axis theory helps account for the association between the CNS and digestive tract involvement in EGPA [26]. Additionally, CNS-affected patients were older, which raises the possibility that age may affect the permeability of the small to medium-sized cerebral vessels and the severity of CNS vascular lesions in EGPA.

Patients with CNS involvement were prescribed more intense therapy, which mainly adopted methylprednisolone pulse or high-dose glucocorticoids combined with CYC. For severely ill patients, we specifically used intrathecal injections of dexamethasone and MTX, which contributed to a favorable clinical response. In 1994, Valesini and his colleagues reported for the first time the intrathecal treatment of central nervous system involvement in systemic lupus erythematosus [27]. Intrathecal injections of MTX 10 mg and dexamethasone 20 mg can bring dramatic therapeutic effects, and the symptoms of the nervous system can be controlled within 24 h. In China, especially in our hospital, this treatment strategy has been used since 1996 and shown good response to patients with CNS involvement of refractory lupus [28]. Gradually, the intrathecal treatment was also applied to CNS involvement of primary vasculitis. And in clinical practice, it has achieved a beneficial effect in some refractory EGPA patients with CNS involvement in China. In addition, high-dose IVIG has been demonstrated to be effective in patients who have failed in high-dose glucocorticoids induction therapy, as observed in our three patients with CNS involvement [29].

Although most patients achieved remission, about 40% of cases relapsed during glucocorticoid reduction, implying that better therapeutics are needed to replace glucocorticoids. Currently, only few types of biological agents have been tried in EGPA, including the B-cell antagonist monoclonal antibody Rituximab, the humanized monoclonal antibody against interleukin-5 Mepolizumab, and the recombinant humanized monoclonal anti-immunoglobulin E antibody Omalizumab. Firstly, for rituximab in China, the indications primarily include follicular B-cell non-Hodgkin’s lymphoma, CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma. And the indications as off-label therapies include chronic graft-versus-host disease, thrombotic thrombocytopenic purpura, chronic lymphocytic leukemia, refractory severe systemic lupus erythematosus, rheumatoid arthritis, GPA, MPA. Therefore, rituximab used in EGPA was just based on the treatment experience of GPA and MPA. Secondly, compared with rituximab, CYC is more affordable, because rituximab is hundreds or even thousands of times more expensive than CYC. Moreover, CYC penetrates the blood–brain barrier more easily than rituximab [30]. Therefore, glucocorticoids combined with CYC are always the first-line therapy for CNS involvement of EGPA.

In recent reviews, rituximab was found it may help induce and sustain remission in patients with newly diagnosed or relapsing EGPA especially for ANCA-positive patients [31, 32]. But in the past, we did not find definite evidence for rituximab in CNS involvement of EGPA. And the ANCA-positive patients were relatively few in our cohort.

Other biological agents were more rarely used in EGPA due to a lack of evidence-based medicine data to prove their effectiveness for CNS involvement in EGPA. For example, mepolizumab was confirmed effective on EGPA-related refractory asthma by randomized clinical trial [33–35], but no clinical trials were conducted for CNS involvement of EGPA. Besides, this biological agent has not yet been marketed in China.

The outcome analysis does not reveal statistical differences between the groups, possibly due to the following reasons: the sample size is not large enough for the nineteen patients with CNS involvement; the follow-up duration is relatively short, and observing sufficient adverse events may require longer follow-up duration. Other studies observed that long-term neurological sequelae were common in CNS involved EGPA patients, occurring in at least half of patients, and were mainly associated with cerebrovascular events [10].

There are limitations to this study. First, this is a single-center retrospective study, and CNS involvement in EGPA is very rare. Thus, the sample size is not large enough, and we could not evaluate the prevalence of CNS involvement in EGPA accurately. Second, most of the patients included in the cohort primarily had worse conditions who were referred from the local hospitals. Therefore, they could not represent a larger EGPA population in China. Thus, we need to enroll more patients with EGPA and continue to follow up to observe the impact of CNS involvement on the long-term survival of EGPA patients.
Conclusions
CNS involvement is uncommon, occurring in 17.3% of EGPA patients. Its manifestations vary widely, including cerebrovascular events, PRES, spinal cord or medulla oblongata involvement, HCP, and cerebellar ataxia. Ischemic lesions are the most frequent manifestations. Age, disease duration, and fever are independent factors associated with CNS involvement in EGPA. After timely treatment of glucocorticoids combined with CYC and intrathecal injections, most patients achieve clinical remission. Acute intracranial hemorrhage and gastrointestinal perforation may be the principal causes of death.

Methods
Patients
We conducted a single-center retrospective case–control study and included 110 EGPA patients from Peking Union Medical College Hospital (PUMCH) between January 2007 and March 2019. This cohort had 19 EGPA patients with CNS involvement as the case group, and 91 EGPA patients without CNS involvement as the control group. All patients fulfilled the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides criteria or the American College of Rheumatology 1990 criteria, and the diagnosis of EGPA was verified by two rheumatologists [36, 37].

For EGPA patients who may have CNS involvement, we systematically evaluated the central nervous system conditions according to their clinical manifestations, physical examinations, MRI and computed tomography scan of the brain or spinal cord, and laboratory testing of CSF. Firstly, we ruled out the CNS lesions caused by other CNS disease-related risk factors, including hypertension, hyperlipidemia, hyperglycemia, smoking, infection, and genetic factors. According to the literature and the recommendation of neurologists, we diagnosed the new onset or relapsing EGPA based on extra-CNS features of EGPA. Concomitantly the manifestations of CNS involvement occurred and responded to immunosuppressive therapy, which were defined as EGPA-related CNS lesions [22].

Manifestations of CNS involvement in EGPA had cerebrovascular events (including ischemic lesions and intracranial hemorrhages), PRES, spinal cord or medulla oblongata involvement, HCP, and cerebellar ataxia. EGPA-related PRES refers to a clinic radiological disorder of reversible vasogenic brain edema in patients with classic acute neurological symptoms, which mainly present with seizures, encephalopathy, headache, and visual disturbances in the setting of EGPA and exclude other possible causes [38, 39]. HCP was diagnosed by contrast-enhanced MRI or computed tomography scan of the brain. Non-CNS entities associated with CNS involvement were analyzed because their anatomical locations were close, and often coincided with CNS involvement.

Considering that this study was based on a retrospective design and that we only used the medical records that did not involve any private information of patients and would not harm them, written informed consent was not given, but oral informed consent was obtained from all enrolled patients by face to face or phone. Additionally, when each patient was admitted to our hospital, our doctors stated that their clinical data might be used for scientific research, and all patients signed the written informed consent at that time. Furthermore, this study was approved by the Medical Ethics Committee of PUMCH (Beijing, China, approval number: S-K1385).

Clinical and laboratory assessments
CSF analysis included pressure (100–180 mmH2O, for adults), appearance (colorless and transparent fluid), protein (0.15–0.45 g/L), and glucose (2.8–4.5 mmol/L). For all EGPA patients, we examined each system included in the Birmingham Vasculitis Activity Score (BVAS) to analyze disease activity [40]. Severe asthma was defined as requiring continuous glucocorticoid therapy (a high dose of inhaled, oral, or intravenous glucocorticoids) or with persistent dyspnea. Cutaneous vasculitis included palpable purpura, reticulata, and gangrene ischemia of the extremities. The definition of arthritis was the symptoms of swelling and pain in multiple joints, accompanied by morning stiffness. Renal involvement was defined as the presence of active urinary sediment (hematuria or cylindruria), proteinuria (urine protein > 0.5 g/24 h), or serum creatinine beyond the upper limit of the normal range. Cardiac involvement included pericardial effusion, myocardial involvement, heart failure, coronary lesions, moderate to severe valve involvement, and arrhythmia, which cannot be explained by other reasons after consultation with experienced cardiologists. Digestive system involvement was defined as gastrointestinal bleeding, intestinal obstruction, or digestive tract conditions that other mechanisms could not explain. Peripheral neuropathy included mononeuritis multiplex and multiple peripheral neuropathy (mononeuritis multiplex meant two or more separate non-adjacent nerve trunks were simultaneously or successively involved, and multiple peripheral neuropathy predominantly affected the distal extremities in a bilaterally symmetrical distribution).

The 2009 revised FFS system [9] and the original 1994 BVAS [40] were used to evaluate the prognosis and disease activity of vasculitis at diagnosis, respectively. The remissions included complete remission and partial relief, which were defined as a BVAS of 0 and a 50% or more
decrease in BVAS compared to the baseline, respectively. The death referred to all-cause mortality.

**Statistical analysis**

Data were described as mean ± standard deviation (SD) for continuous normally distributed data or median (first quartile, third quartile) for continuous non-normally distributed data. And they were compared using the Student’s t-test and Mann–Whitney U test, respectively. Categorical variables were expressed as frequencies and ratios, which were further compared by Chi-square analysis or Fisher’s exact test. Factors with two-sided P < 0.10 were included in the multivariate logistic regression analysis, which was presented with OR and 95% CI. Since FFS includes the factors of age and severe gastrointestinal involvement, we excluded FFS in this model to avoid duplication. Kaplan–Meier survival curves and log-rank tests were used to illustrate and compare the cumulative survival rates (Prism 7; GraphPad, San Diego, CA, USA).

A two-sided P value < 0.05 was considered a statistically significant difference. Statistical analysis was performed using SPSS (Statistical Product and Service Solutions; International Business Machines Corporation25, Armonk, NY, USA).

**Abbreviations**

EGPA: Eosinophilic granulomatosis with polyangiitis; AAV: Antineutrophil cytoplasmic antibody-associated vasculitis; CNS: Central nervous system; PUMCH: Peking Union Medical College Hospital; BVAS: Birmingham Vasculitis Activity Score; FFS: Five-factor score; CSF: Cerebrospinal fluid; MRI: Magnetic resonance imaging; SD: Standard deviation; OR: Odds ratio; CI: Confidence interval; CYC: Cyclophosphamide; MTX: Methotrexate; MG: Intravenous immunoglobulin; GPA: Granulomatosis with polyangiitis; MPA: Microscopic polyangiitis; HCP: Hypertrophic cranial pachymeningitis; PRES: Posterior reversible encephalopathy syndrome.

**Acknowledgements**

We would like to express our great thankfulness to the patients, physicians, nurses, and technicians of PUMCH for their support.

**Authors’ contributions**

WL and ZFC designed the study. LSY analyzed the data and wrote the manuscript. GL, LSY, FXY, and ZZC collected the data. ZJX, TXX, LMT, and WL and ZFC enrolled and managed the clinical care of patients. All authors critically reviewed and approved the final manuscript.

**Funding**

The study was supported by the Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (2019XK230022), National Key Research and Development Program (2016YFA0101003, 2016YFC0903901), National Natural Science Fund (81501414, 81771764, 81571594), CAMS Innovation Fund for Medical Sciences (2017-ICM-3–008, 2016-ICM-1–003).

**Availability of data and materials**

The relevant data used to support the findings of the study are included in the article.

**Declarations**

**Ethics approval and consent to participate**

All patients enrolled in this retrospective study gave their written informed consent. Furthermore, this study was approved by the Medical Ethics Committee of PUMCH (Beijing, China, Ethics Approval Number: S-K1385).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, the Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China. 2. Department of Rheumatology, Dongying People’s Hospital, Dongying 257000, Shandong Province, China. 3. Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. 4. Department of Rheumatology and Clinical Immunology, Gansu Province People’s Hospital, Lanzhou 730000, Gansu Province, China.

**Received:** 10 December 2020  **Accepted:** 16 March 2021  **Published online:** 31 March 2021

**References**

1. Aboul A, Calamia KT, Cohen MD. The Churg Strauss Syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum. 2003;33(2):106–14. https://doi.org/10.1016/s0049-0172(03)00083-0.

2. Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d’Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis withpolyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16(1):1–9. https://doi.org/10.1016/j.autrev.2016.09.018.

3. Oka N, Kawasaki T, Matsui M, Shigematsu K, Uruma T, Sugiyama H. Two subtypes of Churg-Strauss syndrome with neuropathy: the roles of eosphilins and ANCA. Mod Rheumatol. 2011;21(3):290–5. https://doi.org/10.1007/s10909-010-0400-9.

4. Sokolowska WS, A. Włudarczyk, P. Kuczia, B. Jakieła, J. Gąsior, S. Bartyzel, P. Rewierski, J. Musial. ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish centre. Clinical and Experimental Rheumatology. 2014.

5. Mouton L, Dunogue B, Guillemin L. Diagnosis and classification of eosinophilic granulomatosis with polyanigitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48–49:99–103. https://doi.org/10.1016/j.jaut.2014.01.018.

6. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–53. https://doi.org/10.1016/j.ejim.2015.04.022.

7. Samson M, Puechal X, Devillers H, Ribé C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–9. https://doi.org/10.1016/j.jaut.2013.03.003.

8. Guillemin L, Lhotre F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine. 1996;75(1):17–28. https://doi.org/10.1097/00005792-199601000-00003.

9. Guillemin L, Pagnoux C, Seror R, Maehr A, Mouton L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG).
19. de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardised neurologic evaluations of 128 patients with Wegener granulomatosis with polyangiitis: a retrospective single-center study in China. J Immunol Res. 2020;2020:1–10. https://doi.org/10.1155/2020/5530768.

18. Saku A, Furuta S, Hiraguri M, Ikeda K, Kobayashi Y, Kagami S, et al. Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis. J Rheumatol. 2018;45(8):1159. https://doi.org/10.3899/jrheum.171352.

17. Comarmond C, Pagnoux C, Khellaf M, Cordier J-F, Hamidou M, Viallard J-F, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81. https://doi.org/10.1002/art.37721.

16. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine. 1999;78(1):26–37. https://doi.org/10.1097/00005792-199901000-00003.

15. Sinicco RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Central nervous system involvement in ANCA-associated systemic vasculitides. Neurol Neurosurg Psychiatry. 2018;89(1):14–20. https://doi.org/10.1136/jnnp-2017-316225.

14. Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376(20):1921–32. https://doi.org/10.1056/NEJMoa1702079.

13. Mendritto VG, Rossetti G, Olivi D, Angelletti A, Rocchi M, Gabrielli A, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatology. 2021. https://doi.org/10.1093/rheumatology/keab046.

12. Ortega HG, Liu MC, Pavord ID, Brusselle GG, Chetta A, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med. 2014;371(13):1198–207. https://doi.org/10.1056/NEJMoa1403290.

11. Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2014;371(1):98–109. https://doi.org/10.1056/NEJMp1313665.

10. Patel UV, Patel NJ. Posterior reversible leukoencephalopathy syndrome as a presenting manifestation of p-ANCA-associated vasculitis. BMJ Case Reports. 2014. https://doi.org/10.1136/bcr-2013-202022.

9. Fuentes AG, Komarla A, Gomez J, Posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis. Rheumatol Int. 2012;32(8):2529–30. https://doi.org/10.1007/s00296-010-1367-8.

8. Doolan JS, Cohn SD. Systemic lupus erythematosus. Lupus. 2001;10(3):154–61. https://doi.org/10.1076/0961-2093.9.10010006.

7. Valesini G, Priori R, Francia A, Balestrieri G, Tincani A. A selective review of intrathecal methotrexate therapy for systemic lupus erythematosus and the treatment of intrathecal methotrexate plus dexamethasone. Zhonghua Yi Xue Za Zhi. 2006;86(11):771–4.

6. Calabrese LH, Bencivelli W, Porta M, Tincani A, Meziere G, White S, et al. Neurologic evaluations of 128 patients with Wegener granulomatosis. Medicine. 1999;78(1):26–37. https://doi.org/10.1097/00005792-199901000-00003.

5. Fuentes AG, Komarla A, Gomez J, Posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis. Rheumatol Int. 2012;32(8):2529–30. https://doi.org/10.1007/s00296-010-1367-8.

4. Valesini G, Priori R, Francia A, Balestrieri G, Tincani A, Airo P, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol. 1994;16(2):313–21. https://doi.org/10.1007/bf00197524.

3. Zhou HQ, Leng XM, Zhang FC. Neuropsychiatric manifestations in systemic lupus erythematosus and the treatment of intrathecal methotrexate plus dexamethasone. Zhonghua Yi Xue Za Zhi. 2006;86(11):771–4.

2. Turkisawa N, Saito H, Oshikata C, Tsiburai T, Akiyama K. High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis. Clin Transl Allergy. 2014;4(1):1–8.

1. Liu et al. Orphanet J Rare Dis (2021) 16:152 Page 10 of 10

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.